A Trial of Neoadjuvant mFOLFOXIRI Versus CRT in the EMVI Positive LARC
Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
Extramural Vascular Invasion Positive(EMVI+) is a high risk of distant metastasis for locally
advanced rectal cancer(LARC) after resection. The study is to evaluate the efficacy and
safety of FOLFOXIRI as neoadjuvant chemotherapy alone for EMVI+ LARC in contrast to the
efficacy of standard Chemoradiotherapy (CRT).
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Zhejiang Cancer Hospital